NCT05155345View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Mosunetuzumab

Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.

DRUG

Tocilizumab

Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.

Trial Locations (3)

36207

Pinnacle Research Group, Anniston

MD-2025

ICS ARENSIA Exploratory Medicine, Chisinau

85-168

Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Bydgoszcz

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT05155345 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter